RomualdiDDi FlorioCTagliaferriV. The role of anti-müllerian hormone in the characterization of the different polycystic ovary syndrome phenotypes. Reprod Sci. 2016;23(5):655–661.
4.
DingYZhuoG, Zhang C.The Mitochondrial tRNALeu(UUR) A3302G mutation may be associated with insulin resistance in woman with polycystic ovary syndrome. Reprod Sci. 2016;23(2):228–233.
5.
BacallaoKPlaza-ParrochiaFCerdaA. Levels of regulatory proteins associated with cell proliferation in endometria from untreated patients having polycystic ovarian syndrome with and without endometrial hyperplasia. Reprod Sci. 2016;23(2):211–218.
6.
UbbaVSoniUKChadchanS. RHOG-DOCK1-RAC1 signaling axis is perturbed in DHEA-induced polycystic ovary in rat model. Reprod Sci. 2017;24(5):738–752.
7.
LongXLiRYangYQiaoJ. Overexpression of IL-18 in the proliferative phase endometrium of patients with polycystic ovary syndrome. Reprod Sci. 2017;24(2):252–257.
8.
HewlettMChowEAschengrauAMahalingaiahS. Prenatal exposure to endocrine disruptors: a developmental etiology for polycystic ovary syndrome. Reprod Sci. 2017;24(1):19–27.
9.
PadmanabhanVCardosoRCPuttabyatappaM. Developmental programming, a pathway to disease. Endocrinology. 2016;157(4):1328–1340.
10.
de WildeMAEisingJBGunningMN. Cardiovascular and metabolic health of 74 children from women previously diagnosed with polycystic ovary syndrome in comparison with a population-based reference cohort [published online ahead of print]. Reprod Sci. 2018:1933719117749761. doi:10.1177/1933719117749761